Segall Bryant & Hamill’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-37,860
| Closed | -$8.77M | – | 571 |
|
|
2025
Q3 | $8.77M | Sell |
37,860
-2
| -0% | -$407 | 0.12% | 253 |
|
|
2025
Q2 | $7.03M | Hold |
37,862
| – | – | 0.1% | 277 |
|
|
2025
Q1 | $7.93M | Buy |
37,862
+97
| +0.3% | +$18.9K | 0.12% | 250 |
|
|
2024
Q4 | $6.71M | Sell |
37,765
-3,601
| -9% | -$662K | 0.09% | 289 |
|
|
2024
Q3 | $8.17M | Buy |
+41,366
| New | +$7.72M | 0.11% | 260 |
|
|
2023
Q4 | – | Sell |
-157,600
| Closed | -$23.5M | – | 301 |
|
|
2023
Q3 | $23.5M | Sell |
157,600
-1,104
| -0.7% | -$162K | 0.27% | 109 |
|
|
2023
Q2 | $21.4M | Sell |
158,704
-3,856
| -2% | -$565K | 0.22% | 127 |
|
|
2023
Q1 | $25.9M | Sell |
162,560
-1,118
| -0.7% | -$171K | 0.28% | 113 |
|
|
2022
Q4 | $26.5M | Sell |
163,678
-4,300
| -3% | -$659K | 0.3% | 104 |
|
|
2022
Q3 | $22.5M | Sell |
167,978
-1,201
| -0.7% | -$172K | 0.27% | 111 |
|
|
2022
Q2 | $25.9M | Sell |
169,179
-57
| -0% | -$8.71K | 0.29% | 99 |
|
|
2022
Q1 | $27.4M | Sell |
169,236
-4,141
| -2% | -$602K | 0.26% | 108 |
|
|
2021
Q4 | $23.5M | Sell |
173,377
-4,063
| -2% | -$480K | 0.22% | 125 |
|
|
2021
Q3 | $19.1M | Buy |
177,440
+1,156
| +0.7% | +$132K | 0.18% | 139 |
|
|
2021
Q2 | $19.9M | Sell |
176,284
-97
| -0.1% | -$10.9K | 0.19% | 140 |
|
|
2021
Q1 | $19.1M | Sell |
176,381
-9,568
| -5% | -$1.02M | 0.19% | 145 |
|
|
2020
Q4 | $19.9M | Sell |
185,949
-6,927
| -4% | -$666K | 0.22% | 119 |
|
|
2020
Q3 | $16.9M | Sell |
192,876
-13,231
| -6% | -$1.25M | 0.23% | 107 |
|
|
2020
Q2 | $20.2M | Sell |
206,107
-2,207
| -1% | -$194K | 0.34% | 77 |
|
|
2020
Q1 | $15.9M | Sell |
208,314
-11,384
| -5% | -$970K | 0.32% | 75 |
|
|
2019
Q4 | $19.5M | Sell |
219,698
-11,140
| -5% | -$925K | 0.3% | 83 |
|
|
2019
Q3 | $17.5M | Sell |
230,838
-8,464
| -4% | -$580K | 0.27% | 93 |
|
|
2019
Q2 | $17.4M | Sell |
239,302
-16,257
| -6% | -$1.28M | 0.26% | 105 |
|
|
2019
Q1 | $20.6M | Sell |
255,559
-5,009
| -2% | -$410K | 0.32% | 81 |
|
|
2018
Q4 | $24M | Buy |
260,568
+1,946
| +0.8% | +$171K | 0.41% | 62 |
|
|
2018
Q3 | $24.5M | Sell |
258,622
-11,265
| -4% | -$1.07M | 0.36% | 68 |
|
|
2018
Q2 | $25M | Buy |
269,887
+94,168
| +54% | +$9.2M | 0.38% | 66 |
|
|
2018
Q1 | $16.6M | Sell |
175,719
-2,869
| -2% | -$315K | 0.39% | 69 |
|
|
2017
Q4 | $17.3M | Sell |
178,588
-15,647
| -8% | -$1.47M | 0.38% | 73 |
|
|
2017
Q3 | $17.3M | Buy |
194,235
+12,256
| +7% | +$933K | 0.4% | 74 |
|
|
2017
Q2 | $13.2M | Sell |
181,979
-15,434
| -8% | -$1.04M | 0.31% | 85 |
|
|
2017
Q1 | $12.9M | Sell |
197,413
-51,802
| -21% | -$3.26M | 0.31% | 95 |
|
|
2016
Q4 | $15.6M | Sell |
249,215
-5,355
| -2% | -$327K | 0.39% | 79 |
|
|
2016
Q3 | $16.1M | Sell |
254,570
-6,254
| -2% | -$405K | 0.41% | 69 |
|
|
2016
Q2 | $16.1M | Sell |
260,824
-9,434
| -3% | -$575K | 0.43% | 71 |
|
|
2016
Q1 | $15.4M | Buy |
270,258
+1,715
| +0.6% | +$95.6K | 0.38% | 76 |
|
|
2015
Q4 | $15.9M | Sell |
268,543
-1,322
| -0.5% | -$76.1K | 0.38% | 81 |
|
|
2015
Q3 | $14.7M | Buy |
269,865
+8,766
| +3% | +$571K | 0.36% | 82 |
|
|
2015
Q2 | $17.5M | Buy |
261,099
+880
| +0.3% | +$57.5K | 0.39% | 85 |
|
|
2015
Q1 | $15.2M | Buy |
260,219
+2,239
| +0.9% | +$135K | 0.34% | 94 |
|
|
2014
Q4 | $16.9M | Sell |
257,980
-4,722
| -2% | -$298K | 0.38% | 85 |
|
|
2014
Q3 | $15.2M | Sell |
262,702
-1,789
| -0.7% | -$99.3K | 0.35% | 88 |
|
|
2014
Q2 | $14.9M | Sell |
264,491
-14,990
| -5% | -$786K | 0.36% | 94 |
|
|
2014
Q1 | $14.4M | Sell |
279,481
-34,892
| -11% | -$1.76M | 0.34% | 95 |
|
|
2013
Q4 | $16.6M | Buy |
314,373
+15,925
| +5% | +$783K | 0.39% | 85 |
|
|
2013
Q3 | $13.3M | Sell |
298,448
-7,391
| -2% | -$328K | 0.33% | 104 |
|
|
2013
Q2 | $12.6M | Buy |
+305,839
| New | +$13.4M | 0.33% | 101 |
|
Other funds holding ABBV
Segall Bryant & Hamill's ABBV Position: Q4 2025 in Review
Segall Bryant & Hamill sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 37,860 shares — an estimated $8.77M sold.
Segall Bryant & Hamill first reported a position in ABBV in Q2 2013 and held it in 47 quarters. The position peaked at $27.4M in Q1 2022. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.
- Segall Bryant & Hamill reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
- Segall Bryant & Hamill sold 37,860 AbbVie shares in Q4 2025, an estimated $8.77M.
- Segall Bryant & Hamill first reported a position in AbbVie in Q2 2013 and held it in 47 quarters.
- Segall Bryant & Hamill's AbbVie position peaked at $27.4M in Q1 2022.
- 4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.
Based on Segall Bryant & Hamill's 13F filing for Q4 2025, filed 13 Feb 2026.